FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC).
Ari RaphaelElizabeth DudnikDov HershkovitzSuyog JainSteven OlsenLior Soussan-GutmanTaly Ben-ShitritAddie DvirHovav NechushtanNir PeledAmir OnnAbed Agbaryanull On Behalf Of The Israel Lung Cancer GroupPublished in: Journal of clinical medicine (2022)
fusions in aNSCLC may be associated with acquired resistance following treatment with EGFR TKIs. In this clinical scenario, a combination of EGFR TKIs and FGFR TKIs represents a promising treatment strategy.